Core Viewpoint - Tongyun Biotechnology (01332) has seen a significant stock price increase of over 81%, reaching a peak of 0.75 HKD, which represents an almost 900% rise from the opening price of 0.076 HKD on October 30 [1] Company Summary - Tongyun Biotechnology is a wholly-owned subsidiary of Hong Kong-listed Tongyun Biotechnology Group, established in 2020 in Lucheng District, Shanxi Province, with an investment of 370 million HKD to build the world's first large-scale production facility for Rhizoclonium algae [1] - The company has a planned annual production capacity of 20,000 tons of Rhizoclonium algae powder, with the first phase of 4,000 tons having commenced production three months ahead of schedule in March 2023, utilizing a unique acetic acid fermentation process for automated production [1] Strategic Partnership - On October 24, Tongyun Biotechnology signed a strategic cooperation agreement with a sales consortium consisting of Shenzhen Building Supply Chain Technology Co., Ltd., Henan Guozi Marketing Management Co., Ltd., and Beijing He Wan Jia Biotechnology Co., Ltd. [1] - According to the agreement, the consortium will purchase no less than 1 billion HKD worth of Rhizoclonium algae products from Tongyun Biotechnology between 2026 and the end of 2028 [1]

Core Viewpoint - Tuo Yun Bio (01332) has seen a significant stock price increase of nearly 900% since October 30, with a peak of 0.75 HKD and a current price of 0.56 HKD, driven by a strategic partnership agreement for substantial product procurement [1] Company Summary - Shanxi Tuo Yun Bio Technology Co., Ltd., a wholly-owned subsidiary of Tuo Yun Bio Group, has signed a strategic cooperation agreement with a sales consortium for the procurement of no less than 1 billion RMB worth of Rhizoclonium algae products from 2026 to 2028 [1] - The company is recognized as a key project and high-tech enterprise in Shanxi Province, having established the world's first large-scale production facility for Rhizoclonium algae with an investment of 370 million RMB [1] - The facility, located in Lucheng District, is designed to produce 20,000 tons of Rhizoclonium algae powder annually, with the first phase of 4,000 tons having commenced production three months ahead of schedule in March 2023 [1] Industry Summary - The strategic partnership highlights the growing demand for microalgae products, which are increasingly recognized for their potential in various applications, including health and nutrition [1] - The use of proprietary acetic acid fermentation technology in a closed automated production process addresses traditional challenges in the microalgae industry, such as land use and pollution [1]

Core Viewpoint - Green A Bio has successfully obtained FDA certification for its astaxanthin products derived from red algae, marking it as the first company in China's microalgae industry to achieve this dual certification, which signifies a shift from raw material export to brand output in the microalgae sector [1][5] Group 1: Industry Development - The microalgae industry in China has transitioned from being a follower to a leader in technology, with significant advancements made since 2006 when Green A Bio collaborated with the Chinese Academy of Sciences to cultivate red algae strains [3] - Green A Bio has developed proprietary strains of red algae that yield an average astaxanthin content of 2.23% in dry weight, overcoming previous challenges in strain selection and cultivation [4] - The company has innovated a "one-step" cultivation method that integrates all stages of algae growth and astaxanthin accumulation, achieving an extraction efficiency of over 80% and reducing production costs by 30% compared to traditional methods [4][5] Group 2: Brand Recognition and Global Trust - Green A Bio is positioning itself as a leader in the international microalgae market by adhering to pharmaceutical standards in the production of health foods, establishing a comprehensive quality control system across its entire supply chain [6] - The company has successfully exported its products to over 30 countries, including Germany, Italy, and Australia, and has set a precedent for Chinese microalgae companies in the high-end health product market [7] - The recent FDA certification enhances Green A's credibility among international consumers, facilitating its transformation from "China Green A" to "World Green A" and promoting the globalization of Chinese microalgae brands [7][8] Group 3: Future Outlook - The global microalgae market is rapidly expanding, and Chinese companies are increasingly focusing on brand output rather than just raw material exports, indicating an irreversible trend towards globalization [8] - With the leadership of companies like Green A Bio, the Chinese microalgae industry is expected to evolve from being a participant in the global market to becoming a rule-maker and standard-setter, transitioning from a "microalgae power" to a "microalgae stronghold" [8]